



Health Emergency Preparedness and Response Authority

Working with industry and supporting cutting-edge innovation



HERA's mission

HERA mission is to strengthen Europe's preparedness and response to health threats. This implies identifying possible threats, assessing existing countermeasures, establishing stocks or supporting the development of new countermeasures, strengthening supply chains as well as making sure that, if needed, there is sufficient capacity to produce them quickly and at mass.

- Better EU health security coordination in the area of medical countermeasures (MCMs) before and during crises
- Bringing together the EU member states, industry and relevant stakeholders
- Development, production, procurement, stockpiling and equitable distribution of medical countermeasures

“HERA mission is to strengthen Europe's preparedness and response to health threats.”

How is HERA helping in addressing market challenges and failures to boost EU's open strategic autonomy?

- 1** Identifying critical production facilities, manufacturing capacities and ever-warm production sites.
- 2** Identifying supply chain bottlenecks within and outside the EU and market failures that could limit production capacity of medical countermeasures and raw materials during a health crisis, including through collecting feedback from the European Medicine Agency, and industry via the Joint Industrial Cooperation Forum.
- 3** Working with industry and Member States to address bottlenecks and supply chain dependencies within and outside the EU.
- 4** Setting up a Critical Medicines Alliance to allow national authorities, industry, civil society representatives, the Commission and EU agencies to coordinate action at EU level against the shortages of medicines and to address supply chain vulnerabilities.
- 5** Establishing close linkages with and building on the outcomes of relevant programmes and initiatives such as IPCEI Health (Important Project of Common European Interest on Health) and EU FAB.



Joint Industrial Cooperation Forum

The Joint Industrial Cooperation Forum is set up as a subgroup of HERA's Advisory Forum to support collaboration with health-related industrial ecosystems in the area of preparedness and response to health crises. It brings together Member State and industry representatives, and the Commission. Along with the Civil

Society Forum, it provides HERA's Advisory Forum with observations and opinions from a diverse range of interested parties.

Its mandate is to identify and, where possible, reduce congestions within and outside the EU, including market failures and supply chain dependencies that could limit the

production capabilities of relevant medical countermeasures and their raw materials.

The forum will also play a role in contributing to industrial matchmaking events with the aim of creating new industrial partnerships and strengthening overall resilience of the medical supply chains.



Matchmaking and networking

A matchmaking platform where economic operators and developers will be able to flag their capabilities and collaboration needs, has been established. Networking and business relationships has been fostered through the HERA Industry Days, dedicated to medicines and medical countermeasures.



Increasing production in times of need

What is EU FAB?

EU FAB is a network of vaccine manufacturers in the EU with sufficient and agile manufacturing capacities to produce essential vaccines in the event of a health emergency.

How does EU FAB work?

EU FAB members are responsible for ensuring facilities, staff and supply chains are maintained to enable them to quickly start manufacturing at the request of the Commission. EU FAB will have the capacity to produce up to 325 million vaccines per year, within the EU. The network, comprising vaccine producers in the EU, will cover manufacturing capacities for mRNA, vector-based and protein-based vaccines.

What are the objectives of EU FAB?

- Closing the gap between manufacturing and scaling up of vaccine production
- Ensuring the capacity of the industry to produce life-saving medicines
- Reserve manufacturing capacities
- Obtain a priority right for manufacturing of vaccines in case of a future public health emergency

“EU FAB will have the capacity to produce up to 325 million vaccines per year, within the EU.”



Supporting breakthrough innovation

What is HERA Invest?

HERA Invest is the first European health investment fund promoting advanced research and development of medical countermeasures and related technologies, with €100 million dedicated to support innovative SMEs in the late phases of clinical trials, to better prepare and respond to cross-border health threats. Under HERA Invest, the European Investment Bank (EIB) will provide venture loans, covering a maximum of 50% of total project costs.

How does HERA Invest work?

With the EIB as implementing partner, HERA Invest supports innovative companies (particularly SMEs) in late clinical trials, namely companies developing medical countermeasures which tackle one of the following health threats:

- Pathogens with pandemic or epidemic potential
- Chemical, biological, radiological and nuclear (CBRN) threats originating from accidental or deliberate release
- Antimicrobial resistance

What are the objectives of HERA Invest?

- Promote R&D by European companies to ensure open strategic autonomy
- Reduce market failures
- Leverage public funding to incentivize private investment
- Foster the development of new medical countermeasures to protect against health threats

“HERA Invest is the first European health investment fund promoting advanced research and development of medical countermeasures and related technologies, with €100 million dedicated to support innovative SMEs in the late phases of clinical trials.”

